Enzon Pharma (ENZN) – Major News
-
Enzon Pharma (ENZN) Appoints New CEO, CFO; Announces Other Management Changes
-
Enzon Pharma (ENZN) Concludes Sale Review; Declares $1.60/Sh. Special Div.
-
Enzon Pharmaceuticals, Inc. (ENZN) Widens Q4 Loss to 11c/Share
-
Enzon Pharmaceuticals (ENZN) Suspends Clinical Development, To Explore a Sale
-
Enzon Pharmaceuticals, Inc. (ENZN) Swings to Q3 Profit of 8c/Share
-
Enzon Pharmaceuticals, Inc. (ENZN) Narrows Q2 Loss to 2c/Share
-
Enzon Pharmaceuticals, Inc. (ENZN) Swings to Q1 Loss
-
Enzon Pharmaceuticals, Inc. (ENZN) Reports Q4 Loss of $0.10
-
Enzon Pharmaceuticals, Inc. (ENZN) Widens Q3 Loss on Lighter Sales
-
Enzon Pharmaceuticals, Inc. (ENZN) Misses Q2 EPS by 13c
-
Enzon Pharmaceuticals, Inc. (ENZN) Tops Q1 EPS by 4c
-
Enzon Pharma (ENZN) Posts Q3 Loss of 14c, Misses Views; Won't Pursue Pegintron Royalty Stream
-
Enzon Pharmaceuticals Inc. (ENZN) Posts Q1 adj.-Loss of $0.20, Wider than Vews
-
Enzon Pharmaceuticals (ENZN) CEO to Resign
-
Enzon Pharmaceuticals Inc. (ENZN) Posts Q4 Break Even EPS, Beats by 9c
-
Enzon Pharmaceuticals (ENZN) Sells Specialty Pharmaceutical Business for Up to $327M and Royalties
-
Enzon Pharma (ENZN) Reports Breakeven Q3 Results
-
Enzon Pharma (ENZN) Reports Q4 Loss of $0.13, Beats by 3c
-
Enzon Pharma (ENZN) Ends Development of rhMBL, Announces Survivin Antagonist IND Accepted
-
Enzon Pharmaceuticals (ENZN) Reports Q3 Loss of $0.05, Beats by 10c
-
Enzon Pharma (ENZN) To Explore Options for Specialty Pharmaceuticals Business
-
Enzon Pharmaceuticals (ENZN) Reports Q2 Loss of $0.04
-
Enzon Pharmaceuticals (ENZN) Reports Q1 EPS of $0.03, Beats By 12c
-
Enzon Pharmaceuticals (ENZN) Reports Q4 EPS of $0.01, Tops Street Estimate of ($0.28)
Back to ENZN Stock Lookup